Dr. Andreas Rummelt

In his presentation "Sandoz - Increasing value in the generics industry", Dr. Andreas Rummelt spoke about ways and strategies to increase value through value creation using the example of Sandoz International GmbH, a leading global generics company headquartered in Germany.

Andreas Rummelt has been Chief Executive Officer (CEO) of Sandoz, a Novartis company, since November 2004. Sandoz is a leading global generics company that develops, manufactures and markets off-patent or off-patent medicines, biopharmaceuticals, active ingredients and intermediates. Following the acquisition of the generics companies Hexal, Germany, and Eon Labs, USA, by Novartis in 2005, Sandoz has over 20,000 employees in more than 110 countries. The further expansion of the business, the integration of the acquired companies and the realignment of the global strategy and organization are the most important tasks of CEO Andreas Rummelt.

Before taking on this position, Dr. Rummelt was Head of Global Technical Operations at Novartis Pharma AG and a member of the Pharma Executive Committee from 1999 to 2004. At Novartis Pharma AG, he was responsible for the worldwide chemical, pharmaceutical and biotechnological production activities as well as for supply chain and quality management. In this position, he drove the globalization process of the Technical Operations division with its approximately 8,500 employees at the production sites in 16 countries as well as at the Novartis headquarters in Basel. Rummelt placed particular emphasis on quality, delivery reliability, increasing productivity and warehouse optimization.

Andreas Rummelt graduated with a doctorate in pharmacy from the University of Erlangen-Nuremberg, Germany. He completed his executive training in general management and leadership at IMD in Lausanne, INSEAD in Fontainebleau and Harvard Business School in Boston.

In his contribution to the 14th Munich Management Colloquium, Dr. Andreas Rummelt will examine the question of how the value creation of an internationally operating generics company should be structured in order to ensure sustainable and continuous value contributions and thus the existence of the company.

Status: Beginning of 2007